Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
38.83
-0.70 (-1.77%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Septerna Revenue
Septerna had revenue of $26.52M in the quarter ending March 31, 2026, with 12,010.96% growth. This brings the company's revenue in the last twelve months to $72.26M, up 7,295.60% year-over-year. In the year 2025, Septerna had annual revenue of $45.95M with 4,174.51% growth.
Revenue (ttm)
$72.26M
Revenue Growth
+7,295.60%
P/S Ratio
24.23
Revenue / Employee
$555,808
Employees
130
Market Cap
1.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.95M | 44.88M | 4,174.51% |
| Dec 31, 2024 | 1.08M | 924.00K | 611.92% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
SEPN News
- 3 days ago - 3 Small-Cap Stocks Analysts Expect to Rally Big - TipRanks
- 18 days ago - 3 Small-Cap Stocks with ‘Strong Buy’ Ratings and 40%+ Upside, According to Analysts - TipRanks
- 5 weeks ago - Septerna price target raised to $43 from $35 at Truist - TheFly
- 5 weeks ago - Septerna price target lowered to $45 from $52 at Guggenheim - TheFly
- 6 weeks ago - Septerna Transcript: AGM 2026 - Transcripts
- 2 months ago - Septerna initiated with a Buy at Guggenheim - TheFly
- 2 months ago - Septerna to present preclinical characterization of SEP-479 - TheFly
- 2 months ago - Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting - Business Wire